Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120393 · ClinicalTrials.gov registry record · Phase 3
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
A Phase 3 study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
- 14
- Study locations
NCT00120393: Completed Phase 3 study of HIV Infections, sponsored by Bristol-Myers Squibb.
NCT00120393 is a Phase 3 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 192 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (57% lower). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00120393, a Phase 3 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
- 14
- Study locations
Study Summary
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).
Conditions Studied
Interventions
- DRUG atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
- DRUG LPV/r +2 NRTIs (Delayed/optional Switch Group)
Study Locations (14)
California
- Local Institution - Bakersfield
- Local Institution - Los Angeles
- Local Institution - San Francisco
Arizona
- Local Institution - Phoenix
Florida
- Local Institution - Miami
Massachusetts
- Local Institution - Boston
New York
- Local Institution - New York
Ohio
- Local Institution - Cincinnati
Oregon
- Local Institution - Portland
Pennsylvania
- Local Institution - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
What the finished NCT00120393 record still lists
NCT00120393 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (57% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which atazanavir/ritonavir +2 NRTIs (immediate Switch Group) is the first listed.
NCT00120393 lists 14 locations in 12 states (California, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT00120393 about?
NCT00120393 is a clinical study titled "Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir". Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside ...
What is the current status of trial NCT00120393?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2004-01. Estimated completion is 2006-05.
What conditions does trial NCT00120393 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00120393?
The interventions under investigation include: atazanavir/ritonavir +2 NRTIs (immediate Switch Group) (DRUG), LPV/r +2 NRTIs (Delayed/optional Switch Group) (DRUG).
Who is sponsoring clinical trial NCT00120393?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00120393 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00120393's enrollment target sits among peer trials
192 183rd of 542 higher than 360 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia